CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 50 enrolled
Drug / intervention
Platelet-rich plasma injectionprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05390970
NCT05390970Phase 3Completed

Platelet-Rich Plasma Injection for the Treatment of Female Stress Urinary Incontinence: A Randomized Placebo-Controlled Study

Annah J. Vollstedt·interventional·Posted May 25, 2022·Updated Aug 29, 2024

In Brief

A Phase 3 clinical trial evaluating Platelet-rich plasma injection for Urinary Incontinence,Stress and Urinary Incontinence. Completed, enrolled 50 participants across 1 site.

Detailed Summary

The aim of this randomized controlled trial study is to evaluate the efficacy and safety of platelet-rich plasma (PRP) in the treatment of female stress urinary incontinence (SUI), compared to placebo. Subjects will undergo an injection of PRP (or injectable saline placebo) into the anterior vaginal wall in the office. Primary outcomes will include a negative urinary stress test plus improvement with the Patient Global Impression of Improvement (PGI-I) at 6-months. Secondary outcomes will include the Female Sexual Function Index (FSFI), the Incontinence Quality of life (I-QOL), Questionnaire for Urinary Incontinence Diagnosis (QUID), and the visual analog scale for pain.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2023202420252026
First PostedMay 25, 2022
Enrollment StartMay 23, 2022
Primary CompletionDec 13, 2023
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 4.1 years ago

Interventions

Platelet-rich plasma injectionprocedure

Injection of autologous platelet-rich plasma into the anterior vaginal wall